As RFK Jr.'s new vaccine panel ponders changing the hepatitis B vaccination schedule, some doctors recall past patients, ...
A group of advisers to the Centers for Disease Control and Prevention is preparing to vote on whether the agency should scrap ...
The nation's top vaccine advisory panel is expected to debate on Thursday whether to delay the first dose of the hepatitis B ...
1dOpinion
The Journey To Hepatitis B Elimination Through Innovation, Early Testing, And Scientific Discovery
As hepatitis B research progresses, achieving higher functional cure rates is becoming more feasible. It is vital that ...
Delaying the timing of vaccinating infants against hepatitis B — which ACIP could vote on later this week — would likely lead ...
Of the 723 people with Fibrosis-4 Index scores greater than 3.25, indicating advanced fibrosis, and 587 people with diagnosed ...
Despite untreated HBV being linked to earlier mortality, higher all-cause and liver-related death, and a 10% to 25% lifetime risk of developing hepatocellular carcinoma (HCC), only 29% of qualifying ...
GlobalData expects the chronic hepatitis B therapeutics market across major markets to climb from $1.5 billion in 2024 to ...
RNAi is a revolutionary and powerful biotech modality that is being utilized for Chronic Hepatitis B. Investors should heed caution as RNAi has been plagued by clinical failures and setbacks. RNAi ...
Spontaneous loss of hepatitis B e antigen (HBeAg) followed by seroconversion to anti-HBe usually coincides with normalization of serum alanine aminotransferase (ALT) levels, reduction in HBV DNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback